View of Oral etoposide plus anlotinib and subcutaneous envafolimab as a platinum‑free, non‑intravenous first‑line regimen for elderly extensive‑stage small cell lung cancer: a phase II trial with biomarker discovery

Return to Article Details Oral etoposide plus anlotinib and subcutaneous envafolimab as a platinum‑free, non‑intravenous first‑line regimen for elderly extensive‑stage small cell lung cancer: a phase II trial with biomarker discovery Download Download PDF